ANI Pharma (ANIP) Tops Q1 EPS by 12c, Offers FY16 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ANI Pharmaceuticals (ANIP) PT Lifted to $55 at Guggenheim
May 5, 2016 10:18 AM EDTGuggenheim analyst Louise Chen reiterating Buy rating and boosted his price target on ANI Pharmaceuticals (NASDAQ: ANIP) to $55.00 (from $50.00) following Q1 beat. The analyst sees many potential catalysts in 2Q16+.
Chen commented, "Post the 1Q16 beat, we remain positive on ANIP and... More
